Current tumor profiling methods require multiple tests, each targeting a single gene and focusing on specific mutations. Since cancer is a heterogeneous disease, these tests provide only a narrow view of what is actually happening within the tumor. Next-generation sequencing (NGS) as a potential tool for profiling the molecular changes in a tumor can provide more informed personalized therapy decisions. NGS enables:

• A decrease in the need for single-gene/mutation iterative testing that can lengthen time to answer and increase costs
• Sample multiplexing capabilities while retaining the sensitivity of a single test, saving time and money
• Identification of somatic variants associated with specific therapy selections
• The ability to find expression signatures correlated with responses to specific therapy types and prognostic factors

DNA Sequencing Tests

BRAF Mutation Analysis by Next Generation Sequencing

Colon Cancer Panel by Next Generation Sequencing

EGFR Mutation Analysis by Next Generation Sequencing

GIST Panel - KIT, PDGFRA by Next Generation Sequencing

IDH1/IDH2 Mutation Analysis by Next Generation Sequencing

IgVH Somatic Hypermutation by Next Generation Sequencing

KIT Mutations in AML

KRAS Mutation Analysis by Next Generation Sequencing

Lung Cancer Panel by Next Generation Sequencing

Melanoma Cancer Panel by Next Generation Sequencing

MYD88 p.L265P Mutation Analysis by Next Generation Sequencing

Myeloid Extended Mutation Analysis Panel by Next Generation Sequencing

TP53 by Next Generation Sequencing